PCT AND PRO-ADM AS MARKERS FOR MONITORING ANTIBIOTIC TREATMENT

The invention relates to a method for therapy monitoring, comprising prognosis, risk assessment and/or risk stratification of a subsequent adverse event in the health of a patient, comprising providing a sample of said intensive care unit (ICU) patient, wherein medical treatment of said patient has been initiated, wherein the sample is isolated from the patient after admission to the ICU and the treatment initiation, determining a level of proADM or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the likelihood of a subsequent adverse event in the health of said patient, wherein a level of proADM or fragment(s) thereof below a reference level indicates discharging of said patient from ICU, or a level of proADM or fragment(s) thereof above a reference level indicates modifying the treatment of the patient in the ICU.